To the Editor The recent article by Narod et al1 notes that 3% of women who have received a diagnosis of ductal carcinoma in situ (DCIS) die of breast cancer. This figure is independent of whether they have had a local recurrence of invasive disease or in situ disease. I would suggest that the study has identified the small subgroup of pseudo-DCIS, that is, noninvasive breast cancer that is masquerading as invasive through neoductogenesis.
Love SM. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ . JAMA Oncol. 2016;2(3):398-399. doi:10.1001/jamaoncol.2015.4866